Dr. Eunice Wang, MD

Hematology Buffalo, NY Female
NPI: 1386625598
Total Payments
$504,074
2024 Payments
$33,454
Companies
37
Transactions
495
Medicare Patients
840
Medicare Billing
$143,823

Payment Breakdown by Category

Consulting$308,938 (61.3%)
Other$115,371 (22.9%)
Research$40,978 (8.1%)
Travel$27,028 (5.4%)
Food & Beverage$10,889 (2.2%)
Education$869.14 (0.2%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $308,938 103 61.3%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $100,819 40 20.0%
Unspecified $40,978 57 8.1%
Travel and Lodging $27,028 97 5.4%
Honoraria $12,822 6 2.5%
Food and Beverage $10,889 176 2.2%
Compensation for serving as faculty or as a speaker for a medical education program $1,730 1 0.3%
Education $869.14 15 0.2%

Payments by Type

General
$463,096
438 transactions
Research
$40,978
57 transactions

Top Paying Companies

Company Total Records Latest Year
PFIZER INC. $97,266 94 $0 (2023)
JAZZ PHARMACEUTICALS INC. $43,923 38 $0 (2024)
Kite Pharma, Inc. $39,450 37 $0 (2024)
Daiichi Sankyo Inc. $38,666 39 $0 (2024)
Novartis Pharmaceuticals Corporation $35,392 23 $0 (2024)
Gilead Sciences, Inc. $29,188 11 $0 (2024)
Incyte Corporation $24,374 11 $0 (2017)
GlaxoSmithKline, LLC. $24,125 7 $0 (2023)
ABBVIE INC. $23,696 36 $0 (2024)
Stemline Therapeutics Inc. $22,620 16 $0 (2024)

Payment History by Year

Year Amount Transactions Top Company
2024 $33,454 38 Daiichi Sankyo Inc. ($9,952)
2023 $26,562 39 Kite Pharma, Inc. ($7,510)
2022 $45,496 52 Gilead Sciences, Inc. ($12,804)
2021 $70,787 65 Kite Pharma, Inc. ($15,175)
2020 $47,780 34 PFIZER INC. ($12,291)
2019 $73,630 89 PFIZER INC. ($25,206)
2018 $90,507 96 PFIZER INTERNATIONAL LLC ($38,840)
2017 $115,857 82 Incyte Corporation ($24,374)

All Payment Transactions

495 individual payment records from CMS Open Payments — Page 1 of 20

Date Company Product Nature Form Amount Type
12/09/2024 Astellas Pharma Inc — Food and Beverage In-kind items and services $59.23 General
12/08/2024 Astellas Pharma US Inc Xospata (Drug) Food and Beverage In-kind items and services $55.77 General
Category: Oncology
12/07/2024 JAZZ PHARMACEUTICALS INC. VYXEOS (Drug) Food and Beverage In-kind items and services $97.75 General
Category: HEMATOLOGY/ONCOLOGY
12/06/2024 JAZZ PHARMACEUTICALS INC. RYLAZE (Drug) Food and Beverage In-kind items and services $143.43 General
Category: HEMATOLOGY/ONCOLOGY
12/06/2024 Daiichi Sankyo Inc. Vanflyta (Drug) Food and Beverage In-kind items and services $75.00 General
Category: ONCOLOGY
12/06/2024 Daiichi Sankyo Inc. Vanflyta (Drug) Food and Beverage In-kind items and services $30.00 General
Category: ONCOLOGY
12/05/2024 ABBVIE INC. — Food and Beverage In-kind items and services $147.91 General
12/05/2024 ABBVIE INC. — Food and Beverage In-kind items and services $30.44 General
10/02/2024 PharmaEssentia USA Corporation BESREMI (Drug) Food and Beverage In-kind items and services $51.50 General
Category: Oncology
09/05/2024 AstraZeneca Pharmaceuticals LP — Food and Beverage In-kind items and services $99.91 General
09/04/2024 Astellas Pharma US Inc Xospata (Drug) Food and Beverage In-kind items and services $151.33 General
Category: Oncology
09/04/2024 Rigel Pharmaceuticals, Inc. Rezlidhia (Drug), Tavalisse Food and Beverage Cash or cash equivalent $112.57 General
Category: Acute Myeloid Leukemia
07/19/2024 Takeda Pharmaceuticals U.S.A., Inc. ICLUSIG (Drug) Consulting Fee Cash or cash equivalent $3,298.75 General
Category: ONCOLOGY
07/13/2024 Novartis Pharmaceuticals Corporation — Consulting Fee Cash or cash equivalent $2,362.50 General
07/13/2024 Novartis Pharmaceuticals Corporation — Food and Beverage In-kind items and services $150.76 General
07/11/2024 Rigel Pharmaceuticals, Inc. Rezlidhia (Drug), Tavalisse Food and Beverage Cash or cash equivalent $101.56 General
Category: Acute Myeloid Leukemia
06/17/2024 Kite Pharma, Inc. Tecartus (Drug) Consulting Fee Cash or cash equivalent $2,570.00 General
Category: CELLT
06/15/2024 Astellas Pharma US Inc Xospata (Drug) Food and Beverage In-kind items and services $75.66 General
Category: Oncology
06/14/2024 Stemline Therapeutics Inc. ELZONRIS (Drug) Consulting Fee Cash or cash equivalent $2,340.00 General
Category: Oncology
06/14/2024 Stemline Therapeutics Inc. ELZONRIS (Drug) Food and Beverage In-kind items and services $30.66 General
Category: Oncology
06/14/2024 Astellas Pharma US Inc Xospata (Drug) Food and Beverage In-kind items and services $13.24 General
Category: Oncology
06/12/2024 Daiichi Sankyo Inc. Vanflyta (Drug) Consulting Fee Cash or cash equivalent $3,225.00 General
Category: ONCOLOGY
06/01/2024 Rigel Pharmaceuticals, Inc. Rezlidhia (Drug), Tavalisse Food and Beverage Cash or cash equivalent $139.07 General
Category: Acute Myeloid Leukemia
05/31/2024 Kite Pharma, Inc. Tecartus (Drug) Food and Beverage In-kind items and services $50.00 General
Category: CELLT
05/29/2024 Daiichi Sankyo Inc. Vanflyta (Drug) Consulting Fee Cash or cash equivalent $1,290.00 General
Category: ONCOLOGY
123…20»

Research Studies & Clinical Trials

Study Name Company Amount Records
A PHASE I/II, OPEN-LABEL, 2 ARM STUDY TO INVESTIGATE THE SAFETY, CLINI GlaxoSmithKline, LLC. $15,350 1
AML CLINICAL PUBLICATION PROGRAM PFIZER INC. $12,390 10
A Phase 3 Multicenter, Open-label, Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia With FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy Astellas Pharma Global Development $7,194 12
A Phase 3 Open-label Multicenter Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation. Astellas Pharma Global Development $3,146 16
A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy Astellas Pharma Global Development $1,620 8
A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation. Astellas Pharma Global Development $687.97 4
Phase 3, Randomized, Multicenter, Open-Label Trial in Asi Astellas Pharma Global Development $305.00 2
A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation Astellas Pharma Global Development $125.51 2
CL-201 LACEWING Astellas Pharma Global Development $90.40 1
A Study of Gilteritinib, Venetoclax and Azacitidine as a Combned Treatment for People Newly Diagnosed with Acute Myeloid Leukemia Astellas Pharma Global Development $69.03 1

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2023 6 124 284 $64,020 $15,974
2022 5 159 328 $96,764 $23,464
2021 9 323 852 $238,846 $60,961
2020 6 234 700 $184,090 $43,424
Total Patients
840
Total Services
2,164
Medicare Billing
$143,823
Procedure Codes
26

All Medicare Procedures & Services

26 procedure records from CMS Medicare Utilization — Page 1 of 2

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
99215 Established patient office or other outpatient visit, 40-54 minutes Facility 2023 34 58 $23,618 $6,258 26.5%
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes Facility 2023 17 29 $11,126 $2,641 23.7%
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes Facility 2023 13 36 $11,175 $2,179 19.5%
G2212 Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or Facility 2023 29 77 $4,098 $1,834 44.8%
99214 Established patient office or other outpatient visit, 30-39 minutes Facility 2023 19 23 $6,439 $1,639 25.5%
G0316 Prolonged hospital inpatient or observation care evaluation and management service(s) beyond the total time for the primary service (when the primary service has been selected using time on the date of the primary service); each additional 15 minutes by th Facility 2023 12 61 $7,564 $1,422 18.8%
99215 Established patient office or other outpatient visit, 40-54 minutes Facility 2022 39 72 $27,601 $7,871 28.5%
99233 Follow-up hospital inpatient care per day, typically 35 minutes Facility 2022 25 64 $23,392 $5,059 21.6%
99214 Established patient office or other outpatient visit, 30-39 minutes Facility 2022 52 70 $18,570 $4,912 26.5%
99232 Follow-up hospital inpatient care per day, typically 25 minutes Facility 2022 23 86 $25,422 $4,730 18.6%
G2212 Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or Facility 2022 20 36 $1,779 $891.98 50.1%
99215 Established patient outpatient visit, total time 40-54 minutes Facility 2021 70 137 $50,352 $15,729 31.2%
99214 Established patient outpatient visit, total time 30-39 minutes Facility 2021 73 189 $47,808 $14,627 30.6%
99232 Subsequent hospital inpatient care, typically 25 minutes per day Facility 2021 47 234 $66,350 $13,127 19.8%
99233 Subsequent hospital inpatient care, typically 35 minutes per day Facility 2021 40 111 $38,409 $8,949 23.3%
99223 Initial hospital inpatient care, typically 70 minutes per day Facility 2021 15 16 $8,247 $2,500 30.3%
99231 Subsequent hospital inpatient care, typically 15 minutes per day Facility 2021 20 83 $14,145 $2,489 17.6%
99213 Established patient outpatient visit, total time 20-29 minutes Facility 2021 31 41 $7,259 $2,111 29.1%
G2212 Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or Facility 2021 16 30 $1,359 $758.12 55.8%
38222 Diagnostic aspirations and biopsies of bone marrow Facility 2021 11 11 $4,917 $669.90 13.6%
99214 Established patient office or other outpatient, visit typically 25 minutes Facility 2020 68 291 $70,392 $17,869 25.4%
99233 Subsequent hospital inpatient care, typically 35 minutes per day Facility 2020 41 132 $43,356 $10,792 24.9%
99232 Subsequent hospital inpatient care, typically 25 minutes per day Facility 2020 35 144 $38,609 $8,199 21.2%
99213 Established patient office or other outpatient visit, typically 15 minutes Facility 2020 60 96 $16,432 $3,776 23.0%
38222 Bone marrow biopsy and aspiration Facility 2020 16 23 $9,725 $1,434 14.7%
12»

About Dr. Eunice Wang, MD

Dr. Eunice Wang, MD is a Hematology healthcare provider based in Buffalo, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/07/2005. The National Provider Identifier (NPI) number assigned to this provider is 1386625598.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Eunice Wang, MD has received a total of $504,074 in payments from pharmaceutical and medical device companies, with $33,454 received in 2024. These payments were reported across 495 transactions from 37 companies. The most common payment nature is "Consulting Fee" ($308,938).

As a Medicare-enrolled provider, Wang has provided services to 840 Medicare beneficiaries, totaling 2,164 services with total Medicare billing of $143,823. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.

Practice Information

  • Specialty Hematology
  • Other Specialties Hematology & Oncology
  • Location Buffalo, NY
  • Active Since 11/07/2005
  • Last Updated 02/12/2021
  • Taxonomy Code 207RH0000X
  • Entity Type Individual
  • NPI Number 1386625598

Products in Payments

  • VYXEOS (Drug) $40,490
  • Tecartus (Drug) $27,705
  • MYLOTARG (Biological) $25,117
  • RYDAPT (Drug) $22,777
  • ELZONRIS (Drug) $22,620
  • JAKAFI (Drug) $21,934
  • DAURISMO (Drug) $17,065
  • XOSPATA (Drug) $16,065
  • Xospata (Drug) $13,477
  • VENCLEXTA (Drug) $13,113
  • Vanflyta (Drug) $9,952
  • TIBSOVO (Drug) $7,948
  • ICLUSIG (Drug) $7,364
  • Quizartinib (Drug) $6,270
  • BOSULIF (Drug) $4,892
  • Vidaza (Drug) $4,880
  • Rezlidhia (Drug) $3,999
  • Non-Covered Product (Drug) $2,970
  • Revlimid (Drug) $2,536
  • Venclexta (Drug) $2,529

Explore

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Hematology Doctors in Buffalo

Jens Hillengass, Md, MD

Hematology — Payments: $56,043

Hematology $56,043

Devinderpal Randhawa, Md, MD

Hematology — Payments: $5,497

Hematology $5,497

Abul Islam, Md, MD

Hematology — Payments: $4,151

Hematology $4,151

Peter Maslak, Md, MD

Hematology — Payments: $3,500

Hematology $3,500

Ms. Joseph Maher, Md, MD

Hematology — Payments: $261.66

Hematology $261.66

Bora Baysal, Md Phd, MD PHD

Hematology — Payments: $218.15

Hematology $218.15